What is the evidence for palmitoylethanamide in the treatment of neuropathic pain?

Palmitoylethanolamide for Neuropathic Pain

Palmitoylethanolamide (PEA) shows promising evidence as an add-on therapy for neuropathic pain, with the most recent high-quality meta-analysis demonstrating significant pain reduction and quality of life improvements across multiple neuropathic pain conditions, though it is not FDA-approved specifically for neuropathic pain and should be considered as adjunctive rather than first-line therapy.

Current FDA Status and Limitations

The FDA labeling for PEA indicates approval only for "temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises, and sprains" 1. This is a critical distinction—PEA lacks FDA approval for neuropathic pain specifically, which means its use for this indication is off-label.

Evidence Quality and Strength

Most Recent and Highest Quality Evidence

The 2025 meta-analysis by 2 represents the strongest current evidence, analyzing 18 randomized controlled trials with 1,196 patients. This study demonstrates:

• Significant pain reduction at multiple timepoints:

  • 6 weeks: SMD -0.9 (95% CI: -1.60 to -0.31)
  • 8 weeks: SMD -0.98 (95% CI: -1.61 to -0.36)
  • 24-26 weeks: SMD -1.16 (95% CI: -2.15 to -0.17)

• Efficacy across all pain types:

  • Neuropathic pain: SMD -0.97 (95% CI: -1.54 to -0.39)
  • Nociceptive pain: SMD -0.74 (95% CI: -1.42 to -0.06)
  • Nociplastic pain: SMD -0.59 (95% CI: -1.15 to -0.03)

• Quality of life improvements: SMD -0.61 (95% CI: -0.93 to -0.30) 2

Supporting Evidence

The 2023 meta-analysis 3 of 774 patients found PEA reduced pain scores with a standard mean difference of 1.68 (95% CI: 1.05 to 2.31, p = 0.00001), with no major side effects reported.

The 2022 randomized controlled trial 4 specifically in diabetic peripheral neuropathic pain (70 participants, 600 mg daily for 8 weeks) showed:

• Significant reduction in BPI-DPN total pain and pain interference (P ≤ 0.001)
• Improvement in sleep quality (P ≤ 0.001)
• Reduction in depression scores (P = 0.03)
• Decreased IL-6 and CRP levels (P = 0.05)
• 94% study completion rate with excellent tolerability

Critical Contradictory Evidence

The 2016 spinal cord injury study 5 found NO benefit of ultramicronized PEA as add-on therapy in 68 patients with SCI-related neuropathic pain. Mean pain reduction was 0.4 vs 0.7 for placebo (P = 0.46), with no effects on spasticity, insomnia, or psychological functioning. This high-quality negative trial suggests that spinal cord injury neuropathic pain may be refractory to PEA, similar to how the 2010 Mayo Clinic guidelines 6 note that certain neuropathic pain conditions (HIV neuropathy, chemotherapy-induced neuropathy, lumbosacral radiculopathy) are relatively refractory to first-line treatments.

Clinical Application Algorithm

When to Consider PEA:

1. Primary indication: Diabetic peripheral neuropathy with inadequate response to first-line agents (gabapentinoids, SNRIs, TCAs)

2. Secondary indications:

   • Chronic inflammatory demyelinating polyneuropathy (CIDP) as demonstrated in 7
   • Other peripheral neuropathies (excluding SCI-related pain)

3. Dosing: 600 mg twice daily (1,200 mg total daily dose) 1, 4

4. Timeline for assessment: Evaluate efficacy at 4-6 weeks; significant benefits typically emerge by 6-8 weeks 2

When NOT to Use PEA:

• Spinal cord injury-related neuropathic pain (evidence shows no benefit 5)
• As monotherapy for moderate-to-severe neuropathic pain (use as add-on only)
• When first-line agents haven't been adequately trialed

Key Clinical Advantages

• Excellent safety profile: No major adverse effects reported across multiple studies 3, 4, 2
• Anti-inflammatory effects: Reduces IL-6 and CRP levels 4
• Ancillary benefits: Improves sleep quality and mood 4
• Reduces rescue medication needs: Allows for potential reduction in opioid or other analgesic requirements 8

Important Caveats

High heterogeneity exists across studies (I² = 99% in 8), suggesting variable responses depending on pain etiology. The 2010 Mayo Clinic guidelines 6 emphasize that efficacy in one neuropathic pain condition cannot be automatically extrapolated to others—this principle applies directly to PEA.

Publication bias is suggested by funnel plot analysis 8, meaning the true effect size may be smaller than reported.

Formulation matters: Most positive studies used ultramicronized PEA (PEA-um), which has enhanced bioavailability compared to standard formulations 7, 5.

Practical Implementation

Start PEA 600 mg twice daily as add-on therapy to existing neuropathic pain regimen. Assess response at 4-6 weeks using validated pain scales (NRS, NPSI). If no improvement by 8 weeks, discontinue. If beneficial, continue long-term as studies show sustained efficacy up to 24-26 weeks 2. Monitor for quality of life improvements beyond pain scores, as these may be clinically meaningful even with modest pain reduction.